HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G/Wella deal

This article was originally published in The Rose Sheet

Executive Summary

Procter & Gamble's $67.65 (€1= $1.10) offer for Wella preference shares is low and should be increased 30%-50% to be more in line with the $101.48 bid made for Wella's ordinary shares, German accounting firm Susat & Partner says. Susat recently filed a complaint with German financial and securities regulator BaFin on behalf of an investor who holds 5% of Wella preferred shares. P&G maintains its bid is "fair and attractive," as it is 8% higher than the stock's three month premium prior to the acquisition. Henkel bought a 6.86% share in the hair care firm including 10.38% of Wella's preference shares days before P&G announced plans to acquire the company (1"The Rose Sheet" March 17, 2003, p. 4). At an analyst meeting April 14, Henkel CEO Ulrich Lehner stated, "Against the background of the price offered for the ordinary shares, the offer for the preferred shares appears to be very low"...

You may also be interested in...



P&G Tender Offer Increase Adds $86 Mil. To Wella Price Tag

Procter & Gamble increased its offer for Wella preference shares $3.86 (€1=$1.10) to $71.76 per share in a tender offer launched April 28

P&G Possible Wella Buy Complicated By Henkel’s Purchase Of Stake In Firm

A showdown over Wella between Procter & Gamble and Henkel may be developing following the German consu-mer goods manufacturer's announcement March 10 it has acquired a 6.86% stake in the hair care firm

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011162

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel